LumaCyte
Company

Last deal

Amount

Series B

Stage

06.09.2023

Date

3

all rounds

$6.8M

Total amount

General

About Company
LumaCyte revolutionizes cell analysis with its diagnostic tool, accelerating medical discoveries.

Industry

Sector :

Subsector :

Keywords :

Also Known As

Lumacye

founded date

01.01.2012

Number of employees

Company Type

For Profit

Last funding type

Series B

IPO status

Private

Description

LumaCyte is an advanced research and bioanalytics instrumentation company that offers a label-free, single cell analysis tool. Their patented technology, Laser Force Cytology™ (LFC™), measures optical and fluidic forces within a microfluidic channel to analyze cells without the need for antibodies or genetic labeling. This approach broadens the horizons of medical research and expedites breakthroughs. Researchers can better understand diseases, develop therapies faster, and find cures for pressing health concerns. LumaCyte's platform has applications in vaccine development, cell and gene therapy, cancer biology, CAR T-cell immunotherapy, infectious disease, and pre-clinical drug discovery, as well as quality control and process optimization in biomanufacturing. Innovate. Discover. Transform.
Contacts